Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.87 USD
-1.00 (-3.46%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $27.88 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IMVT 27.87 -1.00(-3.46%)
Will IMVT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMVT
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Other News for IMVT
First Week of IMVT August 16th Options Trading
Buy Rating Affirmed for Immunovant Amidst Market Expansion and Promising Clinical Trials
Argenx: Strong Setup For Outperformance In 2025
Immunovant: Overvalued Amidst M&A Speculation
Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive